A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra Abdominal Infections in Hospitalized Adults

AstraZeneca AB0 个研究点目标入组 583 人开始时间: 2013年5月27日最近更新: 2014年6月30日

试验速览

暂无简介。

•1. Patient must be 18 to 90 years of age inclusive.
•2. Female patient is authorized to participate if at least one of the following criteria are met:
•(a) Surgical sterilization
•(b) Age =50 years and postmenopausal as defined by amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments
•(c) Age <50 years and postmenopausal as defined by documented LH and FSH levels in the postmenopausal range PLUS amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments
•(d) Patient has a negative serum pregnancy test (serum ß-human chorionic gonadotropin [ßhCG]) within 1 day prior to study entry, and agrees to use highly effective contraception methods during treatment and for at least 7 days after last dose of IV study therapy.
•3. Intraoperative/postoperative enrollment with confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis.
•4. Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory response; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 466
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 117

•1. Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious.
•2. Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation.
•3. Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis.
•4. Patient is considered unlikely to survive the 6 to 8 week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality.

发起方